Cytokine induced memory-like NK cells(Biohaven Pharmaceuticals)(Cytokine induced memory-like NK cells(Biohaven Pharmaceuticals))

概要

基本信息

药物类型

细胞因子诱导的杀伤细胞疗法

别名-

靶点-

作用机制-

治疗领域

肿瘤免疫系统疾病心血管疾病+ [1]

在研适应症

多发性骨髓瘤

非在研适应症-

原研机构

Biohaven Pharmaceuticals, Inc.

在研机构

Biohaven Pharmaceuticals, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Cytokine induced memory-like NK cells(Biohaven Pharmaceuticals) 相关的临床试验

NCT04634435

/ Recruiting临床1期

A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission

This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission.

开始日期2021-10-21

申办/合作机构

Biohaven Pharmaceuticals, Inc.

[+1]

100 项与 Cytokine induced memory-like NK cells(Biohaven Pharmaceuticals) 相关的临床结果

登录后查看更多信息

100 项与 Cytokine induced memory-like NK cells(Biohaven Pharmaceuticals) 相关的转化医学

登录后查看更多信息

100 项与 Cytokine induced memory-like NK cells(Biohaven Pharmaceuticals) 相关的专利（医药）

登录后查看更多信息

100 项与 Cytokine induced memory-like NK cells(Biohaven Pharmaceuticals) 相关的药物交易

登录后查看更多信息